Scientific Capacity Has Outpaced the Systems That Turn Discoveries Into Cures
Science communicator Saloni Dattani argues that medicine has made substantial, often incremental gains—from steep declines in heart-disease deaths to new vaccines and cancer treatments—but scientific capability alone does not produce cures. In her TED talk, she says treatments are delayed when markets do not reward development, trials cannot recruit enough patients, or research is poorly matched to how diseases spread. Malaria, childhood leukemia and Ebola show how targeted funding, cross-border trial networks and adaptive study designs can turn existing knowledge into lifesaving care.
Medical progress is real, but its gradual gains are easy to miss
Heart disease shows how thoroughly medicine and public health can change a baseline without making the change feel visible. Saloni Dattani notes that, at the same age, people today have roughly one-quarter the chance of dying from heart disease that people had in the 1950s.
US cardiovascular mortality fell steadily from 1933 to 2023 as interventions accumulated: the heart-lung machine, pacemakers, CPR, bypass surgery, emergency-response systems, cardiac imaging, angioplasty and stents, statins and antiplatelet drugs, anti-smoking campaigns, and trans-fat bans. No single breakthrough explains the curve. The improvement accumulated over decades.
Dattani’s point is not that innovation has stopped. Slow, compounding gains are rarely treated as news, even when they transform survival. Her earlier impression was that breakthroughs were isolated events, products of chance or exceptional individual determination. She now sees a continuing stream of medical innovation whose effects can be obscured precisely because they arrive incrementally.
Recent examples include an HIV antiviral that, she says, protects against infection with efficacy “nearly a hundred percent” from a single dose every six months; drugs that reduce cholesterol by 60 percent beyond the effect of statins; and treatments that slow progression of certain lung cancers, brain cancer, and multiple myeloma by half or more. In the past five years, first-ever vaccines arrived for COVID, malaria, chikungunya, and RSV.
Technical capacity does not ensure a treatment
The underlying tools of discovery have become far more capable. Saloni Dattani points to genome sequencing: when the Human Genome Project was completed in 2003, sequencing one person’s genome cost $50 million and took half a year. It now takes under four hours and costs a few hundred dollars.
Microscopy tells a similar story. Over two centuries, Dattani says, resolution improved more than 10,000-fold, from light microscopy through electron microscopy to methods that can resolve atoms and atomic bonds. The source illustrates that progression with RSV: until the 1930s, no one had seen a virus at all; researchers can now see RSV’s atomic structure and design drugs to target it with great precision.
But technical capacity does not determine whether a disease gets a treatment. The obstacles can be financial and institutional: who pays for testing, whether there is a commercial market, whether trials can recruit enough participants, and whether research is organized around the way a disease actually spreads.
Diseases are not a fact of life. They’re problems that we can solve.
Untreatable disease, in Dattani’s account, is not necessarily evidence that the biology is beyond reach. It can reflect a failure to build incentives and institutions adequate to the task.
Malaria illustrates the cost of a missing market
The first malaria vaccine was a scientific achievement that took decades to reach children. Saloni Dattani describes malaria as a difficult target: it is caused by a parasite rather than a virus or bacterium, and that parasite changes form repeatedly during its life cycle. Yet the vaccine introduced only a few years ago had been developed in the 1990s.
Its developers struggled to secure funding for testing at every stage. The central problem, Dattani says, was absent commercial incentive. Developing drugs and vaccines for diseases affecting people in poverty and poorer countries is not profitable, even when millions of children could benefit and the economic payoff could be large. Foreign aid and philanthropy eventually financed the research and testing, but the route from development to vaccination took decades.
That delay is hard to regard as a straightforward success when, as Dattani puts it, half a million children were dying from malaria every year. The relevant question is how to stop the same pattern from recurring.
One answer is an advance market commitment. Donors promise to buy a vaccine at a specified per-dose price, but only if a manufacturer develops a safe and effective product. The commitment gives companies confidence to invest before a product exists; it can also support manufacturing at scale and affordable delivery once it does.
A version of this approach was used in 2009 for pneumococcal vaccines. Vaccines already existed, but they did not cover strains common in Africa and South Asia. Countries and philanthropists funded an advance market commitment for new vaccines, several companies developed them, and Dattani says they reached children faster than usual.
Evidence has to be built around the disease
A missing market is only one kind of bottleneck. Saloni Dattani describes childhood leukemia as a case in which evidence was difficult to produce because the disease was rare. Individual hospitals could not enroll enough patients to run useful clinical trials. Researchers responded by building networks across the United States, and later Europe and Canada, pooling patients from many institutions into larger trials.
That collaboration made it possible to test treatments and learn what worked faster.
| Period | Five-year survival from childhood leukemia |
|---|---|
| Before the 1970s | Around 15% |
| Most recent cohorts shown | Around 85% |
Before the 1970s, only around 15 percent of children with leukemia survived five years after diagnosis. In the two forms shown in the source—acute lymphoblastic and acute myeloid leukemia—the most recent cohorts reach roughly 85 percent survival. Most children in richer countries now survive and are effectively cured, Dattani says. The gains represent thousands of children who would not have lived without the collaboration that made stronger trials possible.
Ebola posed a different research-design problem. There was little commercial incentive to develop a vaccine, and conventional advance-vaccination trials were difficult because outbreaks could not reliably be predicted. Researchers adapted the trial to the disease’s outbreak pattern: once an Ebola case appeared, they rapidly vaccinated people around it. This ring vaccination approach helped test a vaccine that Dattani says is now known to be very effective against the most common Ebola strain.
Progress depends on decisions beyond the laboratory
The examples do not reduce medical innovation to a single policy prescription. They show that different constraints require different forms of organization: funding where a viable market is absent, collaboration where no institution can recruit enough patients alone, and trial designs that work under the conditions in which an outbreak actually occurs.
For Dattani, that is why scientific advances should not be understood as self-executing. Scientists matter, but so do economists, operators, and managers who create the conditions under which a promising intervention can be tested, manufactured, and reach people. The frustrating part of the record is that many breakthroughs might not have happened at all.
The approaches she describes have worked, she says, but have not been used enough. New ones must also be developed, tested, and scaled—particularly amid cuts to science, global health, and foreign aid, when making limited resources go further becomes more urgent.